- Conditions
- Kidney Transplantation
- Interventions
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 76
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End-Stage Renal Disease
- Interventions
- Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Prednisone or methylprednisolone
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 29 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Asthma, Acute Asthma, Reactive Airway Exacerbation
- Interventions
- Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bullous Pemphigoid
- Interventions
- dupilumab, Matching Placebo, Oral corticosteroids (OCS)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more
- Conditions
- IgG4 Related Disease, IgG4-RD
- Interventions
- elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Acute-graft-versus-host Disease
- Interventions
- Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Immunosuppression
- Interventions
- Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone, Mycophenolate Sodium
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
- Interventions
- Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
- Conditions
- Alcoholic Hepatitis
- Interventions
- Anakinra and Zinc, Prednisone, Placebos
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
- Interventions
- Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Marrero, Louisiana • Boston, Massachusetts + 7 more
- Conditions
- Ornithine Transcarbamylase (OTC) Deficiency
- Interventions
- scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
- Interventions
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
- Procedure · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more
- Conditions
- DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
- Interventions
- Cyclosporine, Methylprednisolone and Prednisone
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Glucocorticoid (prednisone or prednisolone)
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Baltimore, Maryland + 7 more
- Conditions
- Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke
- Interventions
- methylprednisolone, prednisolone, prednisone
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
- Interventions
- Belatacept, VIB4920, Thymoglobulin, Methylprednisolone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more
- Conditions
- Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, filgrastim, rituximab, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado